dc.creator | Alexiou, I. | en |
dc.creator | Germenis, A. | en |
dc.creator | Koutroumpas, A. | en |
dc.creator | Kontogianni, A. | en |
dc.creator | Theodoridou, K. | en |
dc.creator | Sakkas, L. I. | en |
dc.date.accessioned | 2015-11-23T10:21:58Z | |
dc.date.available | 2015-11-23T10:21:58Z | |
dc.date.issued | 2008 | |
dc.identifier | 10.1007/s10067-007-0800-1 | |
dc.identifier.issn | 0770-3198 | |
dc.identifier.uri | http://hdl.handle.net/11615/25450 | |
dc.description.abstract | The objective of our study was to establish whether there is an association between rheumatoid arthritis with extra-articular manifestations (exRA) and anti-cyclic citrullinated peptide 2 (anti-CCP2) antibodies in Greeks. A retrospective study of 220 Greek patients with RA, 95 with exRA and 125 without extra-articular manifestations (cRA). Serum anti-CCP2 antibodies and IgM rheumatoid factor (RF) were measured. CCP2(+) were 65.3% of exRA and 58.4% of cRA patients. RF(+) were 69.5% of exRA and 60.0% of cRA patients. Among exRA patients, 37.9% had high serum anti-CCP2 antibody levels (> 100 IU/ml) compared to 21.6% cRA patients (p=0.008). Serositis and pulmonary fibrosis were found to be associated with high levels of anti-CCP2 antibodies (52.9 vs 26.6%, p=0.02 and 63.6 vs 26.8%, p=0.008, respectively). Serum RF levels were 265.0 +/- 52.0 IU/ml (mean +/- SEM) in exRA and 205.1 +/- 40.6 (mean +/- SEM) in cRA (NS). High serum RF levels (> 268 IU/ml) were more likely to have sicca syndrome. In Greek patients with rheumatoid arthritis (RA), high serum anti-CCP2 antibodies are associated with serositis and pulmonary fibrosis. Therefore, anti-CCP2 antibodies have prognostic significance in patients with RA. | en |
dc.source | Clinical Rheumatology | en |
dc.source.uri | <Go to ISI>://WOS:000253974600015 | |
dc.subject | anti-cyclic citrullinated antibodies | en |
dc.subject | autoantibodies | en |
dc.subject | biomarkers | en |
dc.subject | extra-articular manifestations | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | RADIOLOGICAL PROGRESSION | en |
dc.subject | DIAGNOSTIC-VALUE | en |
dc.subject | ANTIBODIES | en |
dc.subject | DISEASE | en |
dc.subject | ASSOCIATION | en |
dc.subject | INFLIXIMAB | en |
dc.subject | Rheumatology | en |
dc.title | Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis | en |
dc.type | journalArticle | en |